How Vital Proteins is Working to Make Collagen Mainstream
In November, Vital Proteins secured $19 Million dollar investment from CAVU Venture Partners. Clayton Christopher and Brett Thomas, Co-Founders and Managing Partners at the firm, join to discuss how they are working with this product to make collagen more mainstream.
Thomas says Vital Proteins product hits on the two big trends in the food product space: protein and ingestible beauty. CAVU predicts collagen will become a $9 Billion market by 2019. Another company CAVU is investing in is Kite Hill, which makes plant-based food products. Christopher says Kite Hill's food technology is innovating the way nut-milk can be transformed into different products, such as yogurt and cream cheese.
When looking at Amazon's impact on the consumer product space, Thomas says he sees more brands looking for new ways to partner with the e-commerce giant. By partnering with Amazon, newer brands are able to get their direct-to-consumer products off the ground.
Amazon blamed "regulatory hurdles" for calling off its proposed acquisition of robot vacuum maker iRobot. Not even a Roomba could clean up the deal's antitrust scrutiny.
To celebrate Flutter Entertainment's debut on the NYSE, FanDuel CEO Amy Howe shares her thoughts on the company's plans for growth, the future of online sportsbetting, and Super Bowl Sunday.
Investopedia's Caleb Silver shares thoughts on the upcoming Fed meeting, why individual investors are still slightly skeptical, and what he's looking for from mega cap tech earnings.
Season's greetings! Tax season, that is. January 29 is the first day you can file your tax return. We walk you through each step — plus a checklist you can download.
The Q-Collar helps protect athletes from impact-related concussions. Now, the U.S. Army is evaluating if the device could help reduce traumatic brain injury cased by blast weapons.
Co-founder and executive chairman of the board at Vaxxinity Lou Reese shares how the company is working to bring vaccines for chronic illnesses like heart disease and Parkinson’s to market with an eye for accessibility.
Mario Veneroso, Kingsview Asset Management Partner, weighs in on the latest economic data and whether the market is pricing in too many rate cuts for the coming year.
